Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO(BMY) · Entity 1662 | Director | March 31, 2006 | April 04, 2006 |
| Emergent BioSolutions Inc.EBS · Entity 5902 | Director | April 30, 2025 | May 03, 2025 |
| UNITED THERAPEUTICS CorpUTHR · Entity 664 | Director | July 22, 2026 | July 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRISTOL MYERS SQUIBB CO
Report date March 31, 2006 · Filed April 04, 2006
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Share UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 22,932.28 |
Reported balance
After 2006-03-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2006-03-31 · Grant · Acquired 203.63 · Balance 22,932.28 F1: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director.
Emergent BioSolutions Inc.
Report date April 30, 2025 · Filed May 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 139,098 |
Reported balance
After 2025-04-30 transaction · row 1
1 source rowRow 1 · 2025-04-30 · Grant · Acquired 34,403 · Balance 139,098 F1: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.45 · Expires 2032-04-29 | Direct | 41,572 |
Reported balance
After 2025-04-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-04-30 · Grant · Acquired 15,824 · Balance 41,572 F2: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. F3: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.
F2: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.
F3: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
UNITED THERAPEUTICS Corp
Report date July 22, 2026 · Filed July 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $527.07 · Expires 2033-07-22 | Direct | 2,380 |
Reported balance
After 2026-07-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-22 · Grant · Acquired 2,380 · Balance 2,380 F3: Annual non-employee director award. F4: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders. |
| Common StockSEC Table I · non-derivative | Direct | 2,983 |
Reported balance
Holding disclosure · report date 2026-07-22 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,983 F1: Total has been updated to correct a clerical error which caused the reporting person's indirect holding of common stock (by trust) to be underreported by 590 shares in the Form 4 filed on July 13, 2026 by the reporting person. These shares are in addition to the 2,903 shares held directly, as reported in the Form 4 filed on July 13, 2026. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 1,457 |
Reported balance
Holding disclosure · report date 2026-07-22 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,457 F2: These securities are held indirectly by a trust over which the reporting person has sole investment power and sole voting power. |
Filing footnotes · ownership attribution and instrument terms
F1: Total has been updated to correct a clerical error which caused the reporting person's indirect holding of common stock (by trust) to be underreported by 590 shares in the Form 4 filed on July 13, 2026 by the reporting person. These shares are in addition to the 2,903 shares held directly, as reported in the Form 4 filed on July 13, 2026.
F2: These securities are held indirectly by a trust over which the reporting person has sole investment power and sole voting power.
F3: Annual non-employee director award.
F4: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 22, 2026 Filed Jul 23, 2026 20:38 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Option · Derivative | 2,380 | $0.00 Strike: $527.07 | $0.00 |
DisclosureSEC source: 0001193522-26-000002 · primarydocument.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,380 Underlying: Common Stock · 2,380 shares Expires 2033-07-22 F3 · shares: Annual non-employee director award. F4 · derivative.exercise_date: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 20:34 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionRestricted Stock Unit · Derivative | 650 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193522-26-000001 · primarydocument.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 650 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares received upon vesting of restricted stock units on July 9, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. F1 · kind: Shares received upon vesting of restricted stock units on July 9, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. F1 · price: Shares received upon vesting of restricted stock units on July 9, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. F3 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 20:34 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 650 | $0.00 | $0.00 |
DisclosureSEC source: 0001193522-26-000001 · primarydocument.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,983 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares received upon vesting of restricted stock units on July 9, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. F1 · price: Shares received upon vesting of restricted stock units on July 9, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 21:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 2,720 | $0.00 Strike: $229.81 | $0.00 |
DisclosureSEC source: 0001193522-25-000004 · primarydocument.xml · derivative · entry 7 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 1,840 Underlying: Common Stock · 2,720 shares Expires 2033-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: These securities are held indirectly by a trust over which the reporting person has sole investment power and sole voting power. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 21:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 3,230 | $0.00 Strike: $183.98 | $0.00 |
DisclosureSEC source: 0001193522-25-000004 · primarydocument.xml · derivative · entry 6 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Common Stock · 3,230 shares Expires 2031-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: These securities are held indirectly by a trust over which the reporting person has sole investment power and sole voting power. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 21:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 4,863 | $512.34 | $2,491,501.15 |
DisclosureSEC source: 0001193522-25-000004 · primarydocument.xml · nonDerivative · entry 4 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · by Trust Disclosed balance after: 0 F3 · price: This transaction was executed in multiple trades at prices ranging from $511.67 to $512.64. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · ownership.nature: These securities are held indirectly by a trust over which the reporting person has sole investment power and sole voting power. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 21:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,087 | $511.22 | $555,699.51 |
DisclosureSEC source: 0001193522-25-000004 · primarydocument.xml · nonDerivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · by Trust Disclosed balance after: 4,863 F2 · price: This transaction was executed in multiple trades at prices ranging from $510.64 to $511.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · ownership.nature: These securities are held indirectly by a trust over which the reporting person has sole investment power and sole voting power. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 21:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 2,720 | $229.81 | $625,083.20 |
DisclosureSEC source: 0001193522-25-000004 · primarydocument.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · by Trust Disclosed balance after: 5,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: These securities are held indirectly by a trust over which the reporting person has sole investment power and sole voting power. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 21:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,230 | $183.98 | $594,255.40 |
DisclosureSEC source: 0001193522-25-000004 · primarydocument.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · by Trust Disclosed balance after: 3,230 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: These securities are held indirectly by a trust over which the reporting person has sole investment power and sole voting power. Read SEC document |
| July 25, 2025 Filed Jul 28, 2025 10:21 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionRestricted Stock Unit · Derivative | 590 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005524 · primarydocument.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · by Trust Disclosed balance after: 0 Underlying: Common Stock · 590 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares received upon vesting of restricted stock units on July 25, 2025. Restricted stock units converted on a one-for-one basis into shares of common stock. F1 · price: Shares received upon vesting of restricted stock units on July 25, 2025. Restricted stock units converted on a one-for-one basis into shares of common stock. F3 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date. F4 · ownership.nature: These restricted stock units were held indirectly by a trust over which the reporting person has sole investment power and sole voting power. Read SEC document |
| July 25, 2025 Filed Jul 28, 2025 10:21 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 590 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005524 · primarydocument.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · by Trust Disclosed balance after: 590 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares received upon vesting of restricted stock units on July 25, 2025. Restricted stock units converted on a one-for-one basis into shares of common stock. F1 · price: Shares received upon vesting of restricted stock units on July 25, 2025. Restricted stock units converted on a one-for-one basis into shares of common stock. F2 · ownership.nature: These common stock shares are held indirectly by a trust over which the reporting person has sole investment power and sole voting power. Read SEC document |
| July 24, 2025 Filed Jul 28, 2025 10:21 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 1,830 | $0.00 Strike: $306.41 | $0.00 |
DisclosureSEC source: 0001562180-25-005524 · primarydocument.xml · derivative · entry 5 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,830 Underlying: Common Stock · 1,830 shares Expires 2035-07-24 F6 · shares: Annual non-employee director award. Read SEC document |
| July 24, 2025 Filed Jul 28, 2025 10:21 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantRestricted Stock Unit · Derivative | 650 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005524 · primarydocument.xml · derivative · entry 4 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650 Underlying: Common Stock · 650 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F6 · shares: Annual non-employee director award. F5 · price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F3 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date. Read SEC document |
| April 30, 2025 Filed May 3, 2025 00:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantStock Option (Right to Buy) · Derivative | 15,824 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001367644-25-000103 · wk-form4_1746232211.xml · derivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,572 Underlying: Common Stock · 15,824 shares Expires 2032-04-29 F2 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. F3 · derivative.underlying_shares: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| April 30, 2025 Filed May 3, 2025 00:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 34,403 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-25-000103 · wk-form4_1746232211.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,098 F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Read SEC document |
| December 19, 2024 Filed Dec 19, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GiftCommon Stock | 1,851 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-008520 · primarydocument.xml · nonDerivative · entry 26 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,200 Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 15,000 | $0.00 Strike: $175.43 | $0.00 |
DisclosureSEC source: 0001562180-24-008520 · primarydocument.xml · derivative · entry 27 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2025-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 100 | $382.25 | $38,224.50 |
DisclosureSEC source: 0001562180-24-008520 · primarydocument.xml · nonDerivative · entry 25 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,051 Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 800 | $381.37 | $305,099.04 |
DisclosureSEC source: 0001562180-24-008520 · primarydocument.xml · nonDerivative · entry 24 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,151 F19 · price: This transaction was executed in multiple trades at prices ranging from $380.88 to $381.63. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 944 | $379.67 | $358,412.35 |
DisclosureSEC source: 0001562180-24-008520 · primarydocument.xml · nonDerivative · entry 23 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,951 F18 · price: This transaction was executed in multiple trades at prices ranging from $379.36 to $380.13. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 400 | $377.46 | $150,984.00 |
DisclosureSEC source: 0001562180-24-008520 · primarydocument.xml · nonDerivative · entry 22 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,895 Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,700 | $375.03 | $1,012,581.00 |
DisclosureSEC source: 0001562180-24-008520 · primarydocument.xml · nonDerivative · entry 21 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,295 F17 · price: This transaction was executed in multiple trades at prices ranging from $374.83 to $375.27. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,962 | $374.17 | $734,115.07 |
DisclosureSEC source: 0001562180-24-008520 · primarydocument.xml · nonDerivative · entry 20 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,995 F16 · price: This transaction was executed in multiple trades at prices ranging from $373.70 to $374.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,525 | $373.06 | $568,914.06 |
DisclosureSEC source: 0001562180-24-008520 · primarydocument.xml · nonDerivative · entry 19 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,957 F15 · price: This transaction was executed in multiple trades at prices ranging from $372.55 to $373.395. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 100 | $370.78 | $37,078.00 |
DisclosureSEC source: 0001562180-24-008520 · primarydocument.xml · nonDerivative · entry 18 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,482 Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,926 | $370.02 | $712,649.28 |
DisclosureSEC source: 0001562180-24-008520 · primarydocument.xml · nonDerivative · entry 17 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,582 F14 · price: This transaction was executed in multiple trades at prices ranging from $369.49 to $370.475. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 752 | $368.67 | $277,238.49 |
DisclosureSEC source: 0001562180-24-008520 · primarydocument.xml · nonDerivative · entry 16 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,508 F13 · price: This transaction was executed in multiple trades at prices ranging from $368.49 to $369.355. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 100 | $382.63 | $38,263.00 |
DisclosureSEC source: 0001562180-24-008520 · primarydocument.xml · nonDerivative · entry 15 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,260 Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 620 | $381.41 | $236,474.51 |
DisclosureSEC source: 0001562180-24-008520 · primarydocument.xml · nonDerivative · entry 14 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,360 F12 · price: This transaction was executed in multiple trades at prices ranging from $381.205 to $381.645. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 700 | $380.12 | $266,084.00 |
DisclosureSEC source: 0001562180-24-008520 · primarydocument.xml · nonDerivative · entry 13 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,980 F11 · price: This transaction was executed in multiple trades at prices ranging from $380.10 to $380.135. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 200 | $379.30 | $75,860.00 |
DisclosureSEC source: 0001562180-24-008520 · primarydocument.xml · nonDerivative · entry 12 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,680 F10 · price: This transaction was executed in multiple trades at prices ranging from $378.91 to $379.69. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 500 | $374.46 | $187,227.70 |
DisclosureSEC source: 0001562180-24-008520 · primarydocument.xml · nonDerivative · entry 11 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,880 F9 · price: This transaction was executed in multiple trades at prices ranging from $377.16 to $378.065. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,200 | $375.00 | $825,006.60 |
DisclosureSEC source: 0001562180-24-008520 · primarydocument.xml · nonDerivative · entry 10 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,380 F8 · price: This transaction was executed in multiple trades at prices ranging from $374.82 to $375.48. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,451 | $374.14 | $917,008.07 |
DisclosureSEC source: 0001562180-24-008520 · primarydocument.xml · nonDerivative · entry 9 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,580 F7 · price: This transaction was executed in multiple trades at prices ranging from $373.70 to $374.585. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 200 | $371.25 | $74,249.00 |
DisclosureSEC source: 0001562180-24-008520 · primarydocument.xml · nonDerivative · entry 8 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,031 Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,501 | $373.12 | $560,048.17 |
DisclosureSEC source: 0001562180-24-008520 · primarydocument.xml · nonDerivative · entry 7 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,231 F6 · price: This transaction was executed in multiple trades at prices ranging from $372.52 to $373.36. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,400 | $370.30 | $518,413.00 |
DisclosureSEC source: 0001562180-24-008520 · primarydocument.xml · nonDerivative · entry 6 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,732 F5 · price: This transaction was executed in multiple trades at prices ranging from $369.95 to $370.79. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,100 | $369.32 | $775,562.55 |
DisclosureSEC source: 0001562180-24-008520 · primarydocument.xml · nonDerivative · entry 5 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,132 F4 · price: This transaction was executed in multiple trades at prices ranging from $368.90 to $369.68. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,307 | $368.50 | $481,632.11 |
DisclosureSEC source: 0001562180-24-008520 · primarydocument.xml · nonDerivative · entry 4 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,232 F3 · price: This transaction was executed in multiple trades at prices ranging from $367.87 to $368.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 600 | $366.97 | $220,183.50 |
DisclosureSEC source: 0001562180-24-008520 · primarydocument.xml · nonDerivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,539 F2 · price: This transaction was executed in multiple trades at prices ranging from $366.545 to $367.37. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,121 | $366.11 | $410,406.73 |
DisclosureSEC source: 0001562180-24-008520 · primarydocument.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,139 F1 · price: This transaction was executed in multiple trades at prices ranging from $365.475 to $366.46. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 15,000 | $175.43 | $2,631,450.00 |
DisclosureSEC source: 0001562180-24-008520 · primarydocument.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,260 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 25, 2024 Filed Jul 26, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantRestricted Stock Unit · Derivative | 590 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-020169 · form4-07262024_040719.xml · derivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 590 Underlying: Common Stock · 590 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F1 · shares: Annual non-employee director award. F2 · derivative.exercise_date: These awards vest on the one-year anniversary of the grant date. F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date. Read SEC document |
| July 25, 2024 Filed Jul 26, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 1,440 | $0.00 Strike: $336.37 | $0.00 |
DisclosureSEC source: 0001415889-24-020169 · form4-07262024_040719.xml · derivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,440 Underlying: Common Stock · 1,440 shares Expires 2034-07-25 F1 · shares: Annual non-employee director award. F2 · derivative.exercise_date: These awards vest on the one-year anniversary of the grant date. Read SEC document |
| May 23, 2024 Filed May 29, 2024 01:14 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantStock Option (Right to Buy) · Derivative | 25,748 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0001367644-24-000079 · wk-form4_1716945287.xml · derivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,748 Underlying: Common Stock · 25,748 shares Expires 2031-05-22 F2 · derivative.exercise_date: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. F3 · derivative.underlying_shares: The number of options granted was determined by dividing half of the total non-employee director compensation value by the Black-Scholes value of a single option calculated as of the date of the grant. Read SEC document |
| May 23, 2024 Filed May 29, 2024 01:14 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 17,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-24-000079 · wk-form4_1716945287.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,695 F1 · shares: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Read SEC document |
| May 03, 2024 Filed May 6, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 5,160 | $0.00 Strike: $119.76 | $0.00 |
DisclosureSEC source: 0001415889-24-012328 · form4-05062024_040501.xml · derivative · entry 4 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,160 shares Expires 2030-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2024 Filed May 6, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,979 | $259.12 | $771,918.18 |
DisclosureSEC source: 0001415889-24-012328 · form4-05062024_040501.xml · nonDerivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,060 F2 · price: This transaction was executed in multiple trades at prices ranging from $258.49 to $259.395. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 03, 2024 Filed May 6, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,181 | $257.39 | $561,366.50 |
DisclosureSEC source: 0001415889-24-012328 · form4-05062024_040501.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,039 F1 · price: This transaction was executed in multiple trades at prices ranging from $256.98 to $257.51. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 03, 2024 Filed May 6, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 5,160 | $119.76 | $617,961.60 |
DisclosureSEC source: 0001415889-24-012328 · form4-05062024_040501.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.